Takeda Exits Cell Therapy Amid Strategic Pivot, Dealing Blow to Once Promising Modality

Takeda is looking to offload its cell therapy platform and preclinical assets to a yet-unidentified external partner. 137 employees will be let go as part of the move.

Scroll to Top